Ultra-high-net-worth families are allocating to healthcare not just for returns — but as a hedge against the most personal risk of all: their own mortality.
"The most sophisticated family offices are no longer asking 'how do we invest in healthcare?' — they are asking 'how do we own the future of human health?'"— Impact Health Family Office Roundtable, 2026
Average healthcare allocation — top-quartile family offices
Family office AUM globally
Return premium vs. public markets — direct health co-investments
From direct investments in longevity biotechs to funding private research consortia, ultra-wealthy families are deploying capital with a deeply personal investment thesis.
The most attractive biotech opportunities rarely reach public markets at reasonable valuations. Here is how family offices are building direct access to Series B and C rounds.
The line between philanthropic capital and investment capital is blurring in healthcare. The families that understand this dynamic are gaining access to the most promising early-stage companies.
"Health is the ultimate asset. Our members are increasingly viewing their healthcare investments not as a sector bet, but as the most important portfolio decision they will ever make."